CR20110604A - Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) adecuados para tratar trastornos que responden a la modulaciën del receptor de serotonina 5-ht - Google Patents

Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) adecuados para tratar trastornos que responden a la modulaciën del receptor de serotonina 5-ht

Info

Publication number
CR20110604A
CR20110604A CR20110604A CR20110604A CR20110604A CR 20110604 A CR20110604 A CR 20110604A CR 20110604 A CR20110604 A CR 20110604A CR 20110604 A CR20110604 A CR 20110604A CR 20110604 A CR20110604 A CR 20110604A
Authority
CR
Costa Rica
Prior art keywords
phenyl
homopiperazine
homopiperazinyl
piperazine
bencensulphonyl
Prior art date
Application number
CR20110604A
Other languages
English (en)
Inventor
Andreas Haupt
Frauke Pohlki
Karla Drescher
Karsten Wicke
Liliane Unger
Ana-Lucia Relo
Anton Bespalov
Barbara Vogg
Juergen DELZER
Min Zhang
Yanbin Lao
Gisela Backfish
Original Assignee
Abbott Lab
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42236832&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20110604(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab, Abbott Gmbh & Co Kg filed Critical Abbott Lab
Publication of CR20110604A publication Critical patent/CR20110604A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos de N-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina), con composiciones farmacéuticas que contienen a los mismos y su uso en terapias. Los compuestos tienen propiedades terapéuticas valiosas y son apropiados, en particular, para tratar enfermedades que responden a la modulación del receptor de serotonina 5-HT6.
CR20110604A 2009-04-30 2011-11-15 Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) adecuados para tratar trastornos que responden a la modulaciën del receptor de serotonina 5-ht CR20110604A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17405409P 2009-04-30 2009-04-30

Publications (1)

Publication Number Publication Date
CR20110604A true CR20110604A (es) 2012-05-28

Family

ID=42236832

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110604A CR20110604A (es) 2009-04-30 2011-11-15 Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) adecuados para tratar trastornos que responden a la modulaciën del receptor de serotonina 5-ht

Country Status (26)

Country Link
US (1) US8076326B2 (es)
EP (1) EP2432769B1 (es)
JP (1) JP5718898B2 (es)
KR (1) KR20120016639A (es)
CN (1) CN102459197B (es)
AR (1) AR076507A1 (es)
AU (1) AU2010243585B2 (es)
BR (1) BRPI1011875A2 (es)
CA (1) CA2759482A1 (es)
CL (1) CL2011002653A1 (es)
CO (1) CO6450637A2 (es)
CR (1) CR20110604A (es)
DO (1) DOP2011000326A (es)
EC (1) ECSP11011468A (es)
ES (1) ES2536779T3 (es)
IL (1) IL215642A (es)
MX (1) MX2011011520A (es)
NZ (1) NZ595698A (es)
PE (1) PE20120881A1 (es)
RU (1) RU2535200C2 (es)
SG (1) SG175187A1 (es)
TW (1) TWI465438B (es)
UA (1) UA107080C2 (es)
UY (1) UY32604A (es)
WO (1) WO2010125134A1 (es)
ZA (1) ZA201107569B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009147190A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
JP5502076B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド 新規化合物
WO2009147188A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Benzpyrazol derivatives as inhibitors of pi3 kinases
US8524751B2 (en) 2009-03-09 2013-09-03 GlaxoSmithKline Intellecutual Property Development 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
US8343959B2 (en) * 2009-04-30 2013-01-01 Abbott Gmbh & Co. Kg N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
RS53830B1 (sr) 2009-04-30 2015-06-30 Glaxo Group Limited Indazoli supstituisani oksazolom kao inhibitori pi3-kinaze
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
WO2012059432A1 (en) * 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
US20140120036A1 (en) * 2012-01-06 2014-05-01 Abbvie Inc. Radiolabeled 5-ht6 ligands
EP2928866A1 (en) * 2012-12-10 2015-10-14 F. Hoffmann-La Roche AG BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS
CN105121404A (zh) * 2013-03-15 2015-12-02 豪夫迈·罗氏有限公司 作为RORc调节剂的芳基磺酰胺和氨基磺酸衍生物
CN104725295B (zh) 2013-12-20 2019-05-24 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
EP3134392B1 (en) 2014-04-19 2019-01-02 Sunshine Lake Pharma Co., Ltd. Sulfonamide derivatives and pharmaceutical applications thereof
US20250228851A1 (en) * 2021-10-20 2025-07-17 Yousef Najajreh Allosteric inhibitor compounds for overcoming cancer resistance

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
IL133870A0 (en) * 1997-07-11 2001-04-30 Smithkline Beecham Plc Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
GB9818916D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9818914D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
SE0002739D0 (sv) 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New use
MXPA03010232A (es) 2001-05-11 2004-03-16 Biovitrum Ab Compuestos de arilsulfonamida, para el tratamiento de la obesidad, de la diabetes tipo ii y de trastornos del sistema nervioso central.
CN100457726C (zh) * 2001-06-11 2009-02-04 比奥维特罗姆股份公开公司 取代的磺酰胺化合物、其制备方法及其作为治疗cns疾病、肥胖和ⅱ型糖尿病的药物的应用
RU2268884C2 (ru) * 2001-08-10 2006-01-27 Ф.Хоффманн-Ля Рош Аг Арилсульфонильные производные, обладающие сродством к рецептору 5-ht6, и способ их получения
EP1476428B1 (en) * 2002-02-22 2010-11-17 Pharmacia & Upjohn Company LLC Pyridyl sulfone derivatives as 5-ht6 receptor ligands
GB0305575D0 (en) 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
WO2006010629A1 (en) 2004-07-28 2006-02-02 Glaxo Group Limited Piperazine derivatives useful for the treatment of gastrointestinal disorders
GB0419192D0 (en) * 2004-08-27 2004-09-29 Merck Sharp & Dohme Therapeutic agents
CN101448803A (zh) * 2006-03-17 2009-06-03 阿斯利康(瑞典)有限公司 用作5-ht6调节剂的四氢萘
TW200812961A (en) * 2006-04-19 2008-03-16 Abbott Gmbh & Co Kg Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor
WO2008087123A2 (en) 2007-01-16 2008-07-24 Solvay Pharmaceuticals B.V. Use of 5-ht6 antagonists to prevent relapse into addiction

Also Published As

Publication number Publication date
JP2012525354A (ja) 2012-10-22
ZA201107569B (en) 2013-04-24
IL215642A0 (en) 2012-01-31
CO6450637A2 (es) 2012-05-31
IL215642A (en) 2015-09-24
PE20120881A1 (es) 2012-08-24
TWI465438B (zh) 2014-12-21
HK1163104A1 (zh) 2012-09-07
KR20120016639A (ko) 2012-02-24
TW201043606A (en) 2010-12-16
US8076326B2 (en) 2011-12-13
CN102459197A (zh) 2012-05-16
AR076507A1 (es) 2011-06-15
WO2010125134A1 (en) 2010-11-04
CL2011002653A1 (es) 2012-06-15
US20100280014A1 (en) 2010-11-04
RU2535200C2 (ru) 2014-12-10
AU2010243585A1 (en) 2011-11-17
SG175187A1 (en) 2011-11-28
EP2432769A1 (en) 2012-03-28
DOP2011000326A (es) 2011-11-15
ES2536779T3 (es) 2015-05-28
JP5718898B2 (ja) 2015-05-13
RU2011148583A (ru) 2013-06-10
NZ595698A (en) 2014-01-31
ECSP11011468A (es) 2011-12-30
UA107080C2 (uk) 2014-11-25
AU2010243585B2 (en) 2014-08-07
EP2432769B1 (en) 2015-04-01
BRPI1011875A2 (pt) 2018-06-19
UY32604A (es) 2010-12-31
CA2759482A1 (en) 2010-11-04
MX2011011520A (es) 2012-06-19
CN102459197B (zh) 2015-08-19

Similar Documents

Publication Publication Date Title
CR20140023A (es) Nuevos compuestos inhibidores de la fosfodiestrerasa tipo 10a
ECSP11011468A (es) Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) adecuados para tratar trastornos que responden a la modulación del receptor de serotonina 5-ht6
MX384905B (es) Degradadores de proteínas de bromodominio y dominioextraterminal (bet).
GT201600233A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
ECSP12011720A (es) Compuestos heterocíclicos y usos de los mismos
MX391720B (es) Terapia combinada para tratar cáncer.
CR11187A (es) Compuestos de quinolina adecuados para el tratamiento de trastornos que responden a la modulacion del receptor de serotonina 5-ht6
BR112017011923A2 (pt) bactéria modificada para tratar doenças associadas com hiperamonemia
ECSP13012573A (es) 6-amino-nicotinamidas sustituidas como moduladores de KCNQ2/3
BR112015018089A2 (pt) moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
MX351028B (es) Determinadadas entidades, composiciones y metodos quimicos.
AR091959A1 (es) Agentes de sosten sinteticos y agentes de sosten monodispersos y metodos para la elaboracion de los mismos
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
ECSP088852A (es) Azolopirimidinas como inhibidores de la actividad canabinoidea 1
CL2008002864A1 (es) Compuestos derivados de 2-amino-quinolina, antagonistas del receptor de serotonina 5-ht 5a; procedimiento de preparacion;composicion farmaceutica; y uso de los compuestos en la prevencion o el tratamiento de depresion,trastornos de ansiedad,esquizofrenia,trastornos de panico,trastornos de memoria,demencia,entre otros.
GT201400222A (es) Agentes para tratar trastornos que implican la modulación de receptores de rianodina
MX2014008705A (es) Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
DOP2021000251A (es) Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b
PA8808201A1 (es) Moduladores imidazolo-,oxazolo-, y tiazolopirimidina del trpvi
MX2020010879A (es) Carboxamidas biciclicas y metodos de uso de las mismas.
MX2017001603A (es) Derivados de piperazina como moduladores de los receptores x del higado.
ECSP10010379A (es) Derivados de oxindol sustituido y su uso para el tratamiento de enfermedades dependientes de la vasopresina
CR11039A (es) Compuestos de quinolina apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5- ht6
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet